Novavax | 8-K: Novavax Pharmaceuticals has expressed its commitment to communicate quickly with the FDA to respond to the PMC request and move forward toward potential approval
Novavax | 144: Notice of proposed sale of securities pursuant to Rule 144
Novavax | 8-K: Current report
Novavax | 4: Statement of changes in beneficial ownership of securities-Director Shiver John W.
Novavax | 3: Initial statement of beneficial ownership of securities-Director Shiver John W.
Novavax | 8-K: Novavax Announces Changes to Board of Directors
Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Trizzino John
Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Kelly James Patrick
Novavax | 8-K: Novavax Pharmaceuticals Announces Termination of Avance Holdings Purchase Agreement with the Government of Canada on March 7, 2025
Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Casey Mark J
Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Draghia-Akli Ruxandra
Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Jacobs John C
Novavax | 4: Statement of changes in beneficial ownership of securities-Officer O'Hara Elaine
Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Kelly James Patrick
Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Trizzino John
Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Casey Mark J
Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Kelly James Patrick
Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Jacobs John C
Novavax | 4: Statement of changes in beneficial ownership of securities-Officer O'Hara Elaine
Novavax | 8-K: Investor Presentation